# # ## ## ## ## ## ## ## |BJ Tremlett|(Deputy|Chair)||| |---|---|---|---|---| |RA Leeds (Honorary||Treasurer)|Resigned|20/02/2023| |R G Maxwell|||Resigned|20/02/2023| |W H T Fenton|||Resigned|26/04/2023| |F R Sims||||| |R H Taylor||||| |S D Crocker|||Appointed|20/02/2023| |N Pearce|||Appointed|20/02/2023| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Sussex Cancer Fund mited by Guarantee Auditor's report (continued) For the Year Endtd 31 March 2023 A further descriptyon of our responsibilitye5 for the audit of the ffinanclal statements is locaod on th¢ Financial Reporung Cttuncll's web51te aL hccpsJlwww.frc.org.uklOur-WorklAUdidAudit￿nd.asSUrlnCe￿tsndard5-?nd.gUld8ncelst8￿dard$￿Ind. guidance-for4udltttrslAuditors-responsibitsoes-for-auditlDescriptioTh-of-auditor5-re5ponsibilities-for-3udiaspx. Thls de5criptlgn fwms part of our auditor's reporL Extsnt to which thtr *Ltdit was considered capable of detectlng Irregularitles. Includlng frxud The obj¥tives of our audi( In respect to frdud, arÈ'. eo identify and 35sess the risks of Material misstatement of the financial staternerbts due w fraud- to obtain $ufficien¢ appropriate audit evidente reEarding the 2sse35ed risks of Material mis$otement due to fraud. through designing and implemeniing appropriate responses.. and to respond appropriately to fraud or suspetted fraud identifiEd during the audit. However. the primary responsibility for the preventyon and detettion of fraud rests with both those charged with governance of the entity ind its tnawernenr. Our approach w35 3$ follows.. We identsfied areas of hw5 anrj r¢gulation5 that couhl reasonably be expetted to have a material effttt on thè financial statements from our general sector experience, and through dixu55i9n with the tnJstees and other management {as required by authting standards), and discussed the trustees and other managernent (he policies and procedures regarding compliance with laws and regulations Isee below),. We identtfied the following areas as those most likely tts have such an effect.. heakh 3nd safety., GeDeral Da(a Pmtection Regulation IGDPR)." fraud: bribery and corruption, and employtnent law. Auditing ttandards limit the required a￿th"c proeedurès tg identify non-compliance these laws and regulations to tftqulry of the trustees and other rnan￿ement and inspection of regulatory and lepl correspotsdeneè, rf any. The identified acwal or suspected non-tompliance wa5 ngt 5uffi¢iently significant to our audit to result in our response bein£ idoncifiod as a key audit matter.. We con5idErEd the legal a￿d regulatory frameworks directty applicable to the financial starements repotting framework IFRS 102, the Companle5 Act 2006 and the ChariEIES ACE 201113nd the relevant tax compliance regukdtlons in the UK. We consldered the nature of the charlty'5 operadon* the eontrol environment and financial perforrnahce. We comThunic3ted identified laws and regularions throughout our team 2nd remain¢d alerr to any indicat49n5 of nonand legacies|||248,890|56,736|305,625|391,328| |Investment
income|||11,929|0|11,929|5,311| |Total income|||260,819|56,736|317,555|396,639| |Expenditure
on:||||||| |Raising funds|||(3,323)|0|(3,323)|(3,046)| |Charitable
activities|||(146,515)|(15,188)|(161,703)|(350,138)| |Total expenditure|||(149,838)|(15,188)|(165,026)|(353,184)| |Net gains/(losses)
on investments||12|(13,100)|0|(13,100)|47,780| |Net income/(expenditure)|||97,881|41,548|139,429|91,235| |Transfers
between|funds|18|(70,029)|70,029|0|0| |Net movement
in funds|||27,852|111,577|139,429|91,235| |Reconciliation
offunds||||||| |Total funds brought|forward||816,283|1,884|818,167|726,932| |Total funds carried forward|||844,135|113,461|957,596|818,167| ## ## ||||||||2023|2022| |---|---|---|---|---|---|---|---|---| |||||||Notes||| |Fixed assets||||||||Restated| |Investments||||||12|545,348|558,448| |Current assets||||||||| |Debtors||||||13|38,500|125,145| |Cash at bank and|||in hand||||819,893|764,351| ||||||||858,393|889,496| |Creditors:|amounts|||falling due within one year||14|(287,665)|(311,481)| |Net current||assets|||||570,728|578,015| |Total assets||less current|||liabilities||1,116,076|1,136,463| |Creditors:|amounts|||falling due after more than one year||15|(158,480)|(318,296)| |Net assets|||||||957,596|818,167| |The funds|ofthe||Trust:|||||| |Restricted|funds|||||18|113,461|1,884| |Unrestricted||funds||||18|844,135|816,283| ||||||||957,596|818,167| |For the Year Ended|31 March 2023|||||||| |---|---|---|---|---|---|---|---|---| ||||||||2023|2022| |||||Notes||||| |Cash flows from operating
activities:
Net income/expenditure
for the year|||||||139,429|91,235| |Unreahsed
(gain)/losses
Dividends
and interest|on investments
from investments|||12|||13,100
(11,929)|(47,780)
(5,311)| |(Increase)/decrease
in
Increase/(decrease)
in|debtors
creditors|||13
14|||86,645
(183,632)|(106,937)
72,189| |Net cash provided|by/(used
in) operating|activities|||||43,613|3,396| |Cash flows from investing
activities:||||||||| |Dividends
and interest|from investments||||||11,929|5,311| |Increase/(decrease)|in cash||||||55,542|8,707| |Cash and cash equivalents
at the beginning|||ofthe year||||764,351|755,644| |Cash and cash equivalents
at the end of||the|year||||819,893|764,351| |Analysis of cash and cash equivalents|||||At|I April|Cash flow|At 31| |||||||2022||March| |||||||||2023| |||||||||6| |Cash at bank and in|hand||||764,351||55,542|819,893| ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ||||Unrestricted|Restricted|Total| |---|---|---|---|---|---| ||||funds|funds|2022| |Income from:|||fs|fs|fs| |||||Restated|| |Donations
and legacies|||391,328||391,328| |Other trading activities:|||||| |Fundraising|||||0| |Investment
income|||5,3 I
I||5,311| |Total income|||396,639|0|396,639| |Expenditure
on:|||||| |Raising funds:|||||| |Fundraising|||(3,046)|0|(3,046)| |Chantable
activities|||(189,852)|(160,286)|(350,138)| |Total expenditure|||(192,898)|(160,286)|(353,184)| |Net gains/(losses)
on investments|||47,780|0|47,780| |Net income/(expenditure)|||251,521|(160,286)|91,235| |Transfers
between|funds||(100,000)|100,000|0| |Net movement
in funds|||151,521|(60,286)|91,235| |Reconciliation
of|funds||||| |Total funds
brought|forward||664,762|62,170|726,932| |Total funds carried forward|||816,283|1,884|818,167| |Income from donations||and legacies|||| |||||2023|2022| |||||6|6| |Donations
and gifts||||289,797|166,841| |Legaoes receivable||||15,829|224,487| |||||305,625|391,328| |Investment
income|||||| |||||2023|2022| |||||6|| |Interest receivable||||11,929|5,311| ## |8|Expenditure||||||| |---|---|---|---|---|---|---|---| ||||Staff|Ocher|Grant|Total|Total| ||||cosTs|cos'ts|funding|2023|2022| |||||||6|6| ||Raising funds||||||| ||Fundraising|||3,323||3,323|3,046| ||Charitable
activities||||||| ||Donation to the Macmillan|Cancer||0|61,089|61,089|55,942| ||Funding
services for the direct|||53,824|0|53,824|72,474| ||benefit of patients
Funding cancer research projects||||(52,047)|(52,047)|160,286| ||Funding of cancer speciahst||||23,644|23,644|0| ||equipment
Support expenditure||52,865|22,327||75,192|61,436| ||||52,865|76,151|32,686|161,703|350,138| ||Total expenditure||52,865|79,474|32,686|165,026|353,184| ## |Analysis o|fsupport costs (including
Governance
cos|ts)|| |---|---|---|---| |||2023|2022| |||6|6| |Wages and|salaries|52,865|49,951| |General office and administration||14,227|3,685| |Governance|costs:||| |Audit fees||8,100|7,800| |||75,192|61,436| ## ## ## ## |Grants payable||||||| |---|---|---|---|---|---|---| ||||||2023|2022| |||||||6| |Net surplus for the||year|is|stated after charging/(crediting):||| |Research grants|||||(52,047)|160,286| |Equipment
grants|||||23,644|| ||||||(28,403)|160,286| |Net grants awarded||during||the year|0|160,286| |Grants previously|awarded|||which are no longer required|(52,047)|0| ||||||(52,047)|160,286| ## ## ## |||||2023|2022| |---|---|---|---|---|---| |||||Number|Number| |Admimstration||and support|staff|2|2| |Employment||costs||2023|2022| |Wages|and social security||costs|49,814|47,100| |Pension|contributions|||3,051|2,851| |||||52,865|49,951| ## |12|Fixed asset|investments|investments|investments|||||| |---|---|---|---|---|---|---|---|---|---| ||||||||||E| ||Fair value at|I April 2022|||||||558,448| ||Change
m value||in the year||||||(13,100)| ||Fair value at|31|March 2023||||||545,348| ||Iffixed assets had not been revalued,||||they would|have been included|at the following|historical cost:|| |||||||||2023|2022| |||||||||E|E| ||Cost|||||||450,000|450,000| |13|Debtors|||||||2023|2022| |||||||||E|E| ||Income tax|recoverable||||||10,000|10,145| ||Prepayments|and accrued incoine||||||28,500|115,000| |||||||||38,500|125,145| |14|Creditors:|amounts||falling due|within one year|||2023|2022| ||Grants
payable|||||||208 476|298,888| ||Trade creditors|||||||10,000|4,793| ||Accruals|||||||69,189|7,800| |||||||||287,665|311,481| |15|Creditors:|amounts||falling due|after more|than one year||2023|2022| |||||||||E|E| ||Grants
payable||1-2years|||||158,480|318,296| |||||||||158,480|318,296| |16|Pension and||other post-retirement
benefit commitments||||||| ||Defined contribution||||||||| |||||||||2023|2022| |||||||||E|f| ||Contributions||payable|by the Trust|for the year|||3,051|2,850| ## ## ## |||||2023|2022| |---|---|---|---|---|---| |||||6|| |Research grants|brought
forward|||617,184|549,121| |Net commitments/(withdrawals)|||made during the year|(52,047)|160,286| |Research grants|paid during|rhe year||(198,181)|(92,023)| |Commitments|at 31 March|2023||366,956|617,384| |Commitments|at 31 March|2023|are payable as follows:||| |Withm
one year||||208,476|298,888| |After more than one year||||158,480|318,296| |||||366,956|617,184| ## ||||||Movement
in funds|Movement
in funds||| |---|---|---|---|---|---|---|---|---| |||||||||Balance| ||||Balance at
April 2022|I|Income|Expenditure|Transfers|at 31
March| |||||||||2023| |||||||||6| ||||Restated|||||| |Restricted|funds||1,884||56,736|(15,188)|70,029|113,461| |Unrestricted||funds||||||| |Protected reserve|||450,000||0|0|(300,000)|150,000| |Designated|funds||||0|0|342,304|342,304| |Undesignated||funds|366283||260819|(162938)|(112,333)|351,831| ||||816,283||260,819|(162,938)|(70,029)|844,135| |Total funds|||818,167||317,555|(178,126)|0|957,596| ## ## |Analysis ofrestricted|funds at 31 March 2023|funds at 31 March 2023|funds at 31 March 2023|||| |---|---|---|---|---|---|---| |Book Fund - provision|ofcancer related
literature|||||493| |Breast Cushions - provision
of equipment||||||3,117| |Chemotherapy
Nurses|- support for NHS|staff||||812| |Haemotology
- support|for haemotology|related research||||42,964| |Equipment||||||12,500| |Haemotology
- support|for haemotology|related research||||27| |Head, Neck fk Thyroid|service support|||||116| |Thancs - support for local cancer related||charity affiliate||||248| |Website development|including
cancer related||literature|||325| |Whizz It Up - provision|of cancer related|literature||||759| |Worthing
Breast Care|- support for Worthmg||Hospital|breast cancer services||52,100| |||||||113,461| |Analysis ofnet assets between
funds||||||| |||||Unrestricted|Restaicted|Total| |||||6||6| |Fund balances at 31 March 2023 are||represented||by:||| |Investments||||545,348|0|545,348| |Current assets||||744,932|113,461|858,393| |Creditors: amounts
falling due within
one year||||(287,665)|0|(287,665)| |Creditors: amounts
falling due after more than|||one year|(158,480)|0|(158,480)| |||||844,135|113,461|957,596| ## ## ## |Analysis of net asset|s betw|een
funds|- Compara|tive
(Restated)|||| |---|---|---|---|---|---|---|---| ||||||Unrestricted|Restricted|Total| |Fund balances at 31|March|2022 are|represented|by:|||| |Investments|||||558,448|0|558,448| |Current assets|||||887,612|1,884|889,496| |Creditors: amounts|falhng|due within|one year||(3 11,481)|0|(311,481)| |Creditors: amounts|falling|due after|more than|one year|(3 18,296)|0|(3 1 8,296)| ||||||816,283|1,884|818,167| ## ##